ArticleEmerging infectious diseases2024
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Is it "Time to Eliminate" Time to Elimination of Symptoms as a Primary Trial End Point for Drugs Targeting Respiratory Viruses?The Journal of infectious diseases · 2026Article
- Academia loses its grip on digital health solutions as innovation in artificial intelligence shifts towards industry.NPJ digital medicine · 2025Review
- COVID-19 Infection, Drugs, and Liver Injury.Journal of clinical medicine · 2025Review
- Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Osage Orange (Pathogens (Basel, Switzerland) · 2025Article
- Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.Biomedicines · 2025Article
- Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.Journal of personalized medicine · 2025Article
- Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19.BMC infectious diseases · 2024Article
- Inactivation of Pseudovirus Expressing the D614G Spike Protein Mutation using Nitric Oxide-Plasma Activated Water.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach.Journal of market access & health policy · 2024Article
- Clinical characteristics and booster vaccine effectiveness of the Omicron variant.BMC infectious diseases · 2024Article
- The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19.The Journal of infectious diseases · 2024Article
- Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.Infectious diseases and therapy · 2024Article
- Article
- Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of SARS-CoV-2 PLpro Enzyme.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2024Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03-0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62-$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36-1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49-$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.